149 related articles for article (PubMed ID: 35767124)
1. Comparative Analysis of All-Cause Health Care Resource Utilization and Costs Among Venous Thrombosis Patients Without Cancer Prescribed Apixaban or VKAs in France.
Mokgokong R; Khachatryan A; Quignot N; Chaves J; Moniot A; Gusto G
Adv Ther; 2022 Aug; 39(8):3766-3776. PubMed ID: 35767124
[TBL] [Abstract][Full Text] [Related]
2. Comparative Clinical and Economic Outcomes Associated with Warfarin Versus Apixaban in the Treatment of Patients with Venous Thromboembolism in a Large U.S. Commercial Claims Database.
Guo JD; Rajpura J; Hlavacek P; Keshishian A; Sah J; Delinger R; Mu Q; Mardekian J; Russ C; Okano GJ; Rosenblatt L
J Manag Care Spec Pharm; 2020 Aug; 26(8):1017-1026. PubMed ID: 32452277
[TBL] [Abstract][Full Text] [Related]
3. Safety, effectiveness, and health care cost comparisons among elderly patients with venous thromboembolism prescribed warfarin or apixaban in the United States Medicare population.
Hlavacek P; Guo JD; Rosenblatt L; Keshishian A; Russ C; Mardekian J; Ferri M; Poretta T; Yuce H; McBane R
Curr Med Res Opin; 2019 Dec; 35(12):2043-2051. PubMed ID: 31387467
[No Abstract] [Full Text] [Related]
4. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and Safety of Oral Anticoagulants in the Treatment of Acute Venous Thromboembolism: A Nationwide Comparative Cohort Study in France.
Bertoletti L; Gusto G; Khachatryan A; Quignot N; Chaves J; Moniot A; Mokgokong R
Thromb Haemost; 2022 Aug; 122(8):1384-1396. PubMed ID: 34983073
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness Analysis for Apixaban in the Acute Treatment and Prevention of Venous Thromboembolism in the Netherlands.
de Jong LA; Dvortsin E; Janssen KJ; Postma MJ
Clin Ther; 2017 Feb; 39(2):288-302.e4. PubMed ID: 28139289
[TBL] [Abstract][Full Text] [Related]
7. Major bleeding risk and healthcare economic outcomes of non-valvular atrial fibrillation patients newly-initiated with oral anticoagulant therapy in the real-world setting.
Lin J; Trocio J; Gupta K; Mardekian J; Lingohr-Smith M; Menges B; You M; Nadkarni A
J Med Econ; 2017 Sep; 20(9):952-961. PubMed ID: 28604139
[TBL] [Abstract][Full Text] [Related]
8. Apixaban versus other anticoagulants in patients with nonvalvular fibrillation: a comparison of all-cause and event-related costs in real-life setting in France.
Belhassen M; Hanon O; Steg PG; Mahé I; Née M; Jacoud F; Dalon F; Cotté FE; Guitard-Dehoux D; Marant-Micallef C; Van Ganse E; Danchin N
Eur J Health Econ; 2023 Aug; 24(6):867-875. PubMed ID: 36030485
[TBL] [Abstract][Full Text] [Related]
9. Apixaban for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: The PAROS cross-sectional study of routine clinical practice.
Falissard B; Picard F; Mahe I; Hanon O; Touzé E; Danchin N; Lamy FX; Ricci L; Steg PG
Arch Cardiovasc Dis; 2019; 112(6-7):400-409. PubMed ID: 31014991
[TBL] [Abstract][Full Text] [Related]
10. Healthcare resource utilization and expenditures among newly-diagnosed elderly non-valvular atrial fibrillation patients initiating oral anticoagulants.
Chowdhury R; Franchino-Elder J; Wang L; Yuce H; Wang C; Hartaigh BO
J Med Econ; 2019 Dec; 22(12):1338-1350. PubMed ID: 31549883
[No Abstract] [Full Text] [Related]
11. Comparison of all-cause costs and healthcare resource use among patients with newly-diagnosed non-valvular atrial fibrillation newly treated with oral anticoagulants.
Gilligan AM; Franchino-Elder J; Song X; Wang C; Henriques C; Sainski-Nguyen A; Wilson K; Smith DM; Sander S
Curr Med Res Opin; 2018 Feb; 34(2):285-295. PubMed ID: 29166800
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
[TBL] [Abstract][Full Text] [Related]
13. Impact of apixaban vs low molecular weight heparin/vitamin k antagonist on hospital resource use in patients with venous thromboembolism.
Browne C; Lanitis T; Hamilton M; Li X; Horbyluk R; Mardekian J; Kongnakorn T; Cohen A
J Med Econ; 2017 Jan; 20(1):98-106. PubMed ID: 27822962
[TBL] [Abstract][Full Text] [Related]
14. A Real-World Cost-Effectiveness Analysis of Rivaroxaban versus Vitamin K Antagonists for the Treatment of Symptomatic Venous Thromboembolism: Lessons from the REMOTEV Registry.
Kepka S; Cordeanu EM; Zarca K; Frantz AS; Ohlmann P; Andres E; Bilbault P; Durand-Zaleski I; Stephan D
Medicina (Kaunas); 2023 Jan; 59(1):. PubMed ID: 36676804
[No Abstract] [Full Text] [Related]
15. Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US.
Amin A; Bruno A; Trocio J; Lin J; Lingohr-Smith M
J Med Econ; 2015 Jun; 18(6):399-409. PubMed ID: 25586203
[TBL] [Abstract][Full Text] [Related]
16. Safety and effectiveness of apixaban compared with warfarin among clinically-relevant subgroups of venous thromboembolism patients in the United States Medicare population.
Guo JD; Hlavacek P; Rosenblatt L; Keshishian A; Russ C; Mardekian J; Ferri M; Poretta T; Yuce H; McBane R
Thromb Res; 2021 Feb; 198():163-170. PubMed ID: 33348190
[TBL] [Abstract][Full Text] [Related]
17. All-Cause, Stroke/Systemic Embolism-, and Major Bleeding-Related Health-Care Costs Among Elderly Patients With Nonvalvular Atrial Fibrillation Treated With Oral Anticoagulants.
Deitelzweig S; Luo X; Gupta K; Trocio J; Mardekian J; Curtice T; Hlavacek P; Lingohr-Smith M; Menges B; Lin J
Clin Appl Thromb Hemost; 2018 May; 24(4):602-611. PubMed ID: 29363999
[TBL] [Abstract][Full Text] [Related]
18. Comparative Safety and Effectiveness of Oral Anticoagulants in Nonvalvular Atrial Fibrillation: The NAXOS Study.
Van Ganse E; Danchin N; Mahé I; Hanon O; Jacoud F; Nolin M; Dalon F; Lefevre C; Cotté FE; Gollety S; Falissard B; Belhassen M; Steg PG
Stroke; 2020 Jul; 51(7):2066-2075. PubMed ID: 32539675
[TBL] [Abstract][Full Text] [Related]
19. Editor's Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials.
Kakkos SK; Kirkilesis GI; Tsolakis IA
Eur J Vasc Endovasc Surg; 2014 Nov; 48(5):565-75. PubMed ID: 24951377
[TBL] [Abstract][Full Text] [Related]
20. Impact of oral anticoagulation choice on healthcare utilization for the primary treatment of venous thromboembolism.
Lutsey PL; MacLehose RF; Claxton JS; Walker RF; Adam TJ; Alonso A; Zakai NA
Vasc Med; 2020 Dec; 25(6):549-556. PubMed ID: 32716254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
